News | March 21, 2022
Lonza signs manufacturing agreement with Oasmia Pharmaceutical
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
The expansion is part of Lonza’s continued investment in its global manufacturing network, aiming to build a comprehensive offering for global customers
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
GOSTAR's proprietary data set underwent rigorous analysis and large-scale ML model building to predict drug solubility in a recent joint study. X-Chem's RosalindAI delivered superior and actionable results than other similar analyses using well-known publically available datasets
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
Under the terms of the agreement, Arrakis will lead research activities for the identification of RNA-targeted small molecule (rSM) binders against a broad set of targets nominated by Amgen
Subscribe To Our Newsletter & Stay Updated
